Janssen Pharmaceuticals is fighting to consolidate a novel Xarelto case into an existing mass-tort program in Philadelphia that, so far, has focused on claims the drug led to excessive bleeding.
Late last month, drugmaker Janssen filed a petition to enforce a case management order from the Xarelto mass-tort program that would consolidate Mothena v. Janssen Research & Development LLC into the existing mass tort in Philadelphia. Plaintiff David Mothena, who is alleging once-daily dosing fails to protect against stroke for 24 hours, responded last week with arguments that his claims do not stem from the same injury, and therefore the case should not be consolidated.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
